Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of h4 agonist molecules for the treatment of idiopathic pulmonary fibrosis

A pulmonary fibrosis and agonist technology, applied in the field of application of H4 agonist molecules for the treatment of idiopathic pulmonary fibrosis, which can solve problems such as no treatment methods

Active Publication Date: 2021-09-17
H4 ORPHAN PHARMA
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0038] As such, currently idiopathic pulmonary fibrosis is a pathology with few real effective commercially available treatments (so far, only ESBRIET for mild and moderate IPF)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of h4 agonist molecules for the treatment of idiopathic pulmonary fibrosis
  • Use of h4 agonist molecules for the treatment of idiopathic pulmonary fibrosis
  • Use of h4 agonist molecules for the treatment of idiopathic pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0061] treatment plan

[0062] All mice (species: C57 / B16J, further referred to as BL6) were subjected to a bleomycin mouse regimen (BLM) of 10 mice per group; these mice were 8-week-old female mice.

[0063] All animals in each group were analyzed for fibrosis separately. The extent of fibrosis was analyzed biochemically, histologically and cytologically using various quantitative and semiquantitative methods.

[0064] All mice BL6 were treated according to the treatment protocol below.

[0065] - Evaluation of 5 groups of mice.

[0066] Treatment with bleomycin (BLM) is carried out according to the following regimen:

[0067] All mice in all groups (except group 1) received bleomycin (BLM) intranasally (via intranasal instillation 3 mg / kg) for 5 consecutive days, and will be monitored every day and will be monitored on D+29 days after BLM instillation. were killed in order to study chronic lung inflammation and fibrosis. Bleomycin was given five times at 8 weeks of ag...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the H4 agonist molecule 1-(7-amino-4,5,6-triethoxy-1-oxo-1,3-dihydro-3-isobenzofuranyl)- Enantiomers of 8‑methoxy‑2‑methyl‑6,7‑methylenedioxy‑, 2,3,4‑tetrahydroisoquinoline or triethoxyquin for the treatment of idiopathic Uses in pulmonary fibrosis.

Description

technical field [0001] The present invention relates to the chemical substance 1-(7-amino-4,5,6-triethoxy-1-oxo-1,3-dihydro-3-isobenzofuranyl)-8-methoxy- The L- and D-enantiomers of 2-methyl-6,7-methylenedioxy-, 2,3,4-tetrahydroisoquinoline or triethoxyquin for use in the treatment of Use in idiopathic pulmonary fibrosis. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) is one of 200 lung diseases in the interstitial lung disease family that affects the pulmonary interstitium, the tissue that lies between the alveolar septa of the lungs. [0003] Idiopathic pulmonary fibrosis is an idiopathic interstitial lung disease, which in turn is an interstitial lung disease, also known as diffuse parenchymal lung disease. [0004] Idiopathic pulmonary fibrosis is a rare disease (prevalence of about 13 to 20 cases per 100,000 inhabitants) that belongs to the most common form in the group of chronically evolving idiopathic diffuse interstitial lung diseases (60% of c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4741A61K9/20A61K9/28A61K9/48A61P11/00
CPCA61K9/0053A61K31/4741A61P11/00A61K9/0056A61K9/006A61K9/0095A61K9/48A61K9/20A61K9/28
Inventor 加埃唐·泰拉斯凯瑟琳·伯尔
Owner H4 ORPHAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com